论文部分内容阅读
异丁基哌嗪力复霉素(R-76—1)由四川抗菌素研究所制成后,经鼠麻风感染模型观察其治疗效果,优于利福平。此后该药对犬的毒力试验,无明显毒性。继我院临床试用R-76-1治疗麻风后,按计划1979年10月在福建省又选择了10例麻风患者进行临床试用,观察该药的毒性及抗麻风疗效。现将福建组R-76-1临床试用三月小结如下: 一、病例选择 试用对象为未经过利福平类药物治疗,细菌指数(BI)在4.0以上,形态指数(MI)在10％左右的界线类偏瘤型(BL)和纯瘤型(LL)麻风临床症状明显的患者。
Isobutylpiperazine microremycin (R-76-1) made by the Sichuan Institute of antibiotics, the model of infection by leprosy to observe its therapeutic effect, superior to rifampicin. Since then the drug toxicity test on dogs, no obvious toxicity. Following our clinical trial of leprosy with R-76-1, 10 leprosy patients were selected for trial in Fujian Province in October 1979 to observe the toxicity and anti-leprosy efficacy. Now the clinical trial of Fujian R-76-1 trial in March are summarized as follows: First, the patients selected for the trial without rifampicin drug treatment, the bacterial index (BI) in more than 4.0, the morphological index (MI) at about 10% Of patients with clinically significant clinical symptoms of borderline off-type (BL) and pure-neoplasia (LL) leprosy.